Anondita completes female latex trials as capacity hits 869m
Key highlights
- Anondita completed female latex-condom trial production in H1 FY27.
- Anondita added 307 million pieces of capacity, taking total capacity to 869 million pieces.
- Anondita reported 15 operational lines, with four under trial and four under process.
- A Rs 91 crore rights issue is intended partly for female latex and non-latex condom manufacturing.
powered by IRIS

Anondita Medicare Limited completed female latex-condom trial production in H1 FY27 and expanded manufacturing capacity by 307 million pieces to 869 million pieces, while management said female non-latex trials were expected within a few months of the November 16, 2026 earnings call. A Rs 91 crore rights issue is intended partly to support both programmes.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
What has Anondita completed in female condoms?
Anondita has completed trial production of female latex condoms, while management expects female non-latex condom trial production within a few months of the November 16, 2026 call. Management said first-phase machinery for the female-condom programme had been installed and that latex trials were already complete.
The female manufacturing segment is Anondita’s main strategic focus for the year, according to management. Management also said that completing the non-latex programme would make Anondita the only company globally making male latex, male non-latex, female latex and female non-latex condoms; this is a company claim, not an independently verified market assessment in the transcript.
Management linked the programme to demand from government and institutional procurement. It said international agencies and non-governmental organisations were increasing their focus on female condoms, while limited manufacturing availability meant some tenders received few participants or remained unserved. The call did not disclose a commercial-sales date, regulatory approval timetable or female-condom revenue target.
How is Anondita expanding manufacturing capacity?
Anondita increased manufacturing capacity by 307 million pieces to 869 million pieces in H1 FY27. The company said it had 15 operational manufacturing lines, four additional lines under trial and another four lines under process at the November 2026 call.
The 869 million-piece capacity figure represented an increase from the company’s previously available manufacturing base, while the eight lines not yet operating show that equipment work was continuing. Management did not split the 869 million pieces between male condoms, female latex condoms and planned female non-latex condoms, so the capacity specifically available for the female programme was not disclosed.
Anondita has also acquired the adjacent D2 and D3 buildings after previously operating from D1, which management described as occupying about one acre. Management said the added premises were needed to create space for higher capacity, connecting the property acquisition to the expansion beyond the existing 15 operating lines.
How is Anondita funding the female-condom programme?
Anondita completed a Rs 91 crore rights issue at Rs 950 per share during the year, with proceeds intended for female latex and female non-latex condom manufacturing, infrastructure, working capital and domestic and international expansion. The company therefore identified the rights issue as a funding source for both female-condom product types rather than assigning all proceeds to a single facility or line.
Management also cited higher revenue and profit metrics against FY26 during the H1 FY27 call. Revenue was reported at Rs 73.54 crore, compared with Rs 54 crore in FY26; earnings before interest, tax, depreciation and amortisation, or EBITDA, were reported at Rs 33 crore, compared with Rs 19.60 crore; and profit after tax was Rs 22 crore, compared with Rs 13 crore.
Management said EBITDA margin was 45%, compared with 36% in FY26, and described the increase as 903 basis points. It also reported a profit-after-tax margin of 29.92%, saying it had improved by 586 points. These figures provide financial context for the Rs 91 crore capital raise, but management did not provide a separate capital-expenditure amount or return target for female condoms.
Got a follow-up? Ask IRIS
What demand and orders has Anondita identified?
Anondita is pursuing government procurement, exports and Cobra-branded sales across markets including Nepal, Bangladesh, Bhutan, Brazil, South Africa, Kenya and the United Arab Emirates. Management said it was building its own-brand presence alongside government contracts, including in markets where it was already supplying institutional customers.
The company reported completing its first 10 export containers, worth Rs 9 crore, and said customers had paid advances for a further 40 containers. Those remarks concerned condom exports generally, rather than female condoms specifically, so they do not establish female-condom sales or confirm that the new female latex product has entered regular commercial supply.
Management gave two different government-order figures for the next six months. It first referred to orders worth Rs 68 crore, then later described Rs 70 crore of domestic government orders, Rs 40 crore of South African orders and Rs 40 crore of own-brand orders in hand. The Rs 2 crore difference means the precise government-order figure was not consistent within the November 16 call.
Management said purchase orders for some National AIDS Control Organisation, or NACO, supplies had been delayed by transfers and postings at the Ministry of Health, and were subsequently received. It also said it had been shortlisted as the lowest bidder, or L1, for some products. These comments describe the order flow for existing business and do not confirm future tender awards for female non-latex condoms.
Conclusion
Anondita’s female-condom programme has moved through latex trial production, supported by a 307 million-piece capacity addition that brought total capacity to 869 million pieces and by a Rs 91 crore rights issue. The reported revenue increase to Rs 73.54 crore from Rs 54 crore and EBITDA increase to Rs 33 crore from Rs 19.60 crore provide the financial backdrop, while the company has not disclosed female-condom revenue or a launch date.
The next disclosed milestone is female non-latex trial production within a few months of the November 16, 2026 call. Investors can also watch progress on the four lines under trial and four lines under process, the conversion of tender interest into purchase orders, and any clarification of the government-order value that management cited as both Rs 68 crore and Rs 70 crore.


